AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30072277 — intervention group
Group type: COMPARATOR
Intervention: Control group (electrodes placed but device not started).
Number of subjects: 52
Study 30078086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 0
Study 30078086 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib plus Methotrexate
Number of subjects: 0
Study 30078086 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 26950160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspersed condition (practice questions every 1-2 slides)
Number of subjects: 301
Study 26950160 — intervention group
Group type: COMPARATOR
Intervention: At-the-end condition (practice questions at the end of the presentation)
Number of subjects: 301
Study 26950160 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspersed condition (practice questions throughout lectures)
Number of subjects: 301
Study 26950160 — intervention group
Group type: COMPARATOR
Intervention: At-the-end condition (practice questions at the end of the lectures)
Number of subjects: 301
Study 24826447 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 60
Study 24826447 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60
Study 24826447 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 60
Study 22426706 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care providers (PCP)
Number of subjects: 100000
Study 22426706 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a PCP
Number of subjects: 100000
Study 22426706 — intervention group
Group type: COMPARATOR
Intervention: Patients without a PCP
Number of subjects: 100000
Study 20338817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain quality (throbbing and itchy pain)
Number of subjects: 0
Study 17628437 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management program with food provision
Number of subjects: 0
Study 16210665 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/d of fish oil
Number of subjects: 50
Study 16210665 — intervention group
Group type: COMPARATOR
Intervention: 2 g/d of soy oil
Number of subjects: 50
Study 12358655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg x kg(‐1)
Number of subjects: 60
Study 12358655 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.01 mg.kg‐1
Number of subjects: 60
Study 12358655 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antiemetic (Control group)
Number of subjects: 60
Study 10194077 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocomponent pertussis toxoid vaccine
Number of subjects: 781
Study 7590425 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 16
Study 7590425 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 200 mg
Number of subjects: 16
Study 7590425 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 100 mg
Number of subjects: 16
Study 7590425 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 2156416 — intervention group
Group type: EXPERIMENTAL
Intervention: CT plus MPA
Number of subjects: 89
Study 2156416 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 89
Study 6893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (0.3 mg/kg i.v. bolus)
Number of subjects: 0
Study 6893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (3 CU/kg/h i.v. infusion)
Number of subjects: 0
Study 6893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and pirenzepine
Number of subjects: 0
Study 6893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin (10 CU/kg s.c. and 0.5 CU/kg/h i.v.)
Number of subjects: 0
Study 6893378 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 0
Study 31286817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive health checks offered by general practitioners
Number of subjects: 549
Study 29105631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic cream containing 4% Saussurea lappa extract
Number of subjects: 0
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1% in 1 eye
Number of subjects: 200
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine-treated eyes
Number of subjects: 200
Study 25640408 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eye
Number of subjects: 200
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors
Number of subjects: 200
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 200
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline myopia
Number of subjects: 200
Study 25640408 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic change in untreated eyes
Number of subjects: 200
Study 24096465 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity, home-based walking program
Number of subjects: 66
Study 24096465 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 66
Study 21846395 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 73
Study 19948613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 25% dextrose treatment, given 2 minutes before the injection
Number of subjects: 640
Study 19948613 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact, initiated 2 minutes before the injection and persisting throughout the procedure
Number of subjects: 640
Study 19948613 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral 25% dextrose treatment and skin-to-skin contact
Number of subjects: 640
Study 19948613 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (routine)
Number of subjects: 640
Study 16493214 — intervention group
Group type: EXPERIMENTAL
Intervention: End-firing Nd:YAG laser
Number of subjects: 62
Study 16493214 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-firing Nd:YAG laser
Number of subjects: 62
Study 15035552 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of oocyte retrieval (Group A)
Number of subjects: 103
Study 15035552 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (Utrogestan, Besins International) 400 mg starting on the day of embryo transfer (Group B)
Number of subjects: 103
Study 10834419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 60
Study 10834419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9569795 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF 40 mg
Number of subjects: 100
Study 9569795 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 500 mg
Number of subjects: 100
Study 9569795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8371917 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (35 micrograms/ml)
Number of subjects: 60
Study 8371917 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (60 micrograms/ml)
Number of subjects: 60
Study 8371917 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (115 micrograms/ml)
Number of subjects: 60
Study 8371917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8371917 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41 (all concentrations)
Number of subjects: 60
Study 3524514 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-86 (muscarinic agonist) administered orally at maximum individually tolerated dose levels for eight days
Number of subjects: 8
Study 3524514 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 31753521 — intervention group
Group type: EXPERIMENTAL
Intervention: MHADRO intervention group
Number of subjects: 836
Study 29505772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg every 6 hours
Number of subjects: 100
Study 29505772 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg every 6 hours
Number of subjects: 100
Study 26618259 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital impression technique
Number of subjects: 42
Study 26618259 — intervention group
Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 42
Study 24420746 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz 600 mg/day
Number of subjects: 12
Study 24420746 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg with rifampin 600 mg/day
Number of subjects: 12
Study 22372850 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert source condition (psychological oncological expert talking about cancer patients' experiences)
Number of subjects: 154
Study 22372850 — intervention group
Group type: COMPARATOR
Intervention: Former patient source condition
Number of subjects: 154
Study 20934562 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 4124
Study 20934562 — intervention group
Group type: COMPARATOR
Intervention: No hormone replacement therapy (non-HRT)
Number of subjects: 4124
Study 20934562 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 4124
Study 18547757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (20mg BID for 2 weeks, then 40mg BID for 10 weeks)
Number of subjects: 265
Study 18547757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 18547757 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 265
Study 15199033 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser treatment (fluence of 3 J/cm2)
Number of subjects: 40
Study 15199033 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated skin)
Number of subjects: 40
Study 11325157 — intervention group
Group type: EXPERIMENTAL
Intervention: Hi-Dense fillings (condensable metal-reinforced glass ionomer cement)
Number of subjects: 17
Study 9012902 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium/oxygen (He/O2) inhalation for 90 minutes
Number of subjects: 12
Study 7936810 — intervention group
Group type: EXPERIMENTAL
Intervention: IUGR infants
Number of subjects: 47
Study 3060885 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 12.103 A
Number of subjects: 41
Study 3060885 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 41
Study 30316339 — intervention group
Group type: EXPERIMENTAL
Intervention: Living liver donation (LLD) related
Number of subjects: 2683
Study 30316339 — intervention group
Group type: EXPERIMENTAL
Intervention: Living liver donation (LLD) unrelated
Number of subjects: 2683
Study 30316339 — intervention group
Group type: EXPERIMENTAL
Intervention: Various factors influencing attitude towards LLD
Number of subjects: 2683
Study 28663621 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (0.3 mg)
Number of subjects: 25
Study 28663621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 26557673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with antioxidants/omega 3 fatty acids (A/ω3) for three months
Number of subjects: 148
Study 26557673 — intervention group
Group type: COMPARATOR
Intervention: Computer users (CUG)
Number of subjects: 148
Study 23301559 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzocaine mucoadhesive patches (20%)
Number of subjects: 30
Study 23301559 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 30
Study 21970447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 38
Study 21970447 — intervention group
Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 38
Study 21970447 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance + resistance training (ER)
Number of subjects: 38
Study 18450232 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of ondansetron intravenously 30 minutes prior to completion of the surgery
Number of subjects: 372
Study 18450232 — intervention group
Group type: COMPARATOR
Intervention: 4 mg of ondansetron intravenously prior to the induction of anesthesia
Number of subjects: 372
Study 18450232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 372
Study 17557432 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of pseudoephedrine sulfate and 10 mg of domperidone at bedtime for 30 days (open-label trial)
Number of subjects: 30
Study 17557432 — intervention group
Group type: COMPARATOR
Intervention: 60 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Number of subjects: 30
Study 17557432 — intervention group
Group type: COMPARATOR
Intervention: 30 mg of pseudoephedrine sulfate plus 10 mg of domperidone (placebo-controlled trial)
Number of subjects: 30
Study 17557432 — intervention group
Group type: COMPARATOR
Intervention: Drug combination (pseudoephedrine sulfate and domperidone)
Number of subjects: 30
Study 15058039 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone and pentoxifylline
Number of subjects: 42
Study 15058039 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 42
Study 15058039 — intervention group
Group type: COMPARATOR
Intervention: antibiotics only
Number of subjects: 42
Study 10716106 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed treatment (77 patients)
Number of subjects: 137
Study 10716106 — intervention group
Group type: COMPARATOR
Intervention: Open treatment (65 patients)
Number of subjects: 137
Study 9360163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low temperature WBHT for 1 hour at 40 degrees C, repeated 96 hours later
Number of subjects: 30
Study 9360163 — intervention group
Group type: EXPERIMENTAL
Intervention: High temperature WBHT for 1 hour at 42 degrees C, repeated 96 hours later
Number of subjects: 30
Study 9360163 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 30
Study 9360163 — intervention group
Group type: EXPERIMENTAL
Intervention: WBHT in patients on protease inhibitor/triple drug therapy
Number of subjects: 30
Study 1550466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 387
Study 1550466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 387
Study 1550466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d and 20 mg/d
Number of subjects: 387
Study 1550466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 3898350 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine maintenance therapy
Number of subjects: 86
Study 3898350 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 86
Study 30889827 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (TKD)
Number of subjects: 37
Study 30889827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 29106772 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training for 6 months
Number of subjects: 46
Study 29106772 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 46
Study 27528611 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL hyaluronic acid (HA) injection at the end of arthroscopic meniscectomy
Number of subjects: 90
Study 27528611 — intervention group
Group type: COMPARATOR
Intervention: Meniscectomy alone
Number of subjects: 90
Study 23924070 — intervention group
Group type: EXPERIMENTAL
Intervention: KOH 10% solution applied two times a day until lesions disappeared
Number of subjects: 30
Study 23924070 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy performed with liquid nitrogen spray, repeated weekly for 4 weeks
Number of subjects: 30
Study 22699672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated fiber post (LP)
Number of subjects: 345
Study 22699672 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized fiber post (ES)
Number of subjects: 345
Study 22699672 — intervention group
Group type: COMPARATOR
Intervention: No post retention (A)
Number of subjects: 345
Study 22699672 — intervention group
Group type: COMPARATOR
Intervention: Teeth with one coronal wall
Number of subjects: 345
Study 22699672 — intervention group
Group type: COMPARATOR
Intervention: Teeth with two coronal walls
Number of subjects: 345
Study 22699672 — intervention group
Group type: COMPARATOR
Intervention: Teeth with three coronal walls
Number of subjects: 345
Study 22699672 — intervention group
Group type: COMPARATOR
Intervention: Teeth without coronal walls
Number of subjects: 345
Study 20196969 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 g of n-3 polyunsaturated fatty acids (n-3 PUFA) daily for 24 weeks
Number of subjects: 138
Study 20196969 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 138
Study 17540474 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate size 17 cm
Number of subjects: 119
Study 17540474 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate size 22 cm
Number of subjects: 119
Study 17540474 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate size 26 cm
Number of subjects: 119
Study 17540474 — intervention group
Group type: EXPERIMENTAL
Intervention: Smallest plate in third study
Number of subjects: 119
Study 15242867 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm guided by oesophageal Doppler flowmetry to maintain a stroke index above 35 ml/m2
Number of subjects: 174
Study 15242867 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodynamic management
Number of subjects: 174
Study 11591936 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy
Number of subjects: 55
Study 11591936 — intervention group
Group type: COMPARATOR
Intervention: Open hepatectomy
Number of subjects: 55
Study 9676822 — intervention group
Group type: COMPARATOR
Intervention: m-CPP (0.08 mg/kg i.v.) + placebo
Number of subjects: 11
Study 9676822 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP (0.08 mg/kg i.v.) + ondansetron (0.15 mg/kg i.v.)
Number of subjects: 11
Study 9676822 — intervention group
Group type: COMPARATOR
Intervention: ondansetron (0.15 mg/kg i.v.) + placebo
Number of subjects: 11
Study 9676822 — intervention group
Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 11
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 40 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 60 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 75 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 150 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 300 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 600 mg/min
Number of subjects: 56
Study 8053580 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion rate of 1200 mg/min
Number of subjects: 56
Study 2922026 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate drops
Number of subjects: 12431
Study 2922026 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ophthalmic ointment
Number of subjects: 12431
Study 2922026 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline ophthalmic ointment
Number of subjects: 12431
Study 2922026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 12431
Study 29575232 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend Index-guided propofol delivery
Number of subjects: 40
Study 29575232 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical parameters for propofol delivery (Control)
Number of subjects: 40
Study 27997805 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC) set at 40 L/min
Number of subjects: 15
Study 27997805 — intervention group
Group type: COMPARATOR
Intervention: Standard nonocclusive facial mask
Number of subjects: 15
Study 25271991 — intervention group
Group type: EXPERIMENTAL
Intervention: Icare Pro rebound tonometer
Number of subjects: 50
Study 25271991 — intervention group
Group type: COMPARATOR
Intervention: Tono-Pen XL tonometer
Number of subjects: 50
Study 25271991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent eye in lateral decubitus position
Number of subjects: 50
Study 25271991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both spherical equivalents and axial lengths
Number of subjects: 50
Study 22915617 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (ADA+MTX)
Number of subjects: 0
Study 22915617 — intervention group
Group type: COMPARATOR
Intervention: Monotherapies (control group)
Number of subjects: 0
Study 21154013 — intervention group
Group type: EXPERIMENTAL
Intervention: 30MIN (75 g isomaltulose, 75% reduced insulin dose)
Number of subjects: 7
Study 21154013 — intervention group
Group type: COMPARATOR
Intervention: 60MIN
Number of subjects: 7
Study 21154013 — intervention group
Group type: COMPARATOR
Intervention: 90MIN
Number of subjects: 7
Study 21154013 — intervention group
Group type: COMPARATOR
Intervention: 120MIN
Number of subjects: 7
Study 18279292 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressings
Number of subjects: 76
Study 18279292 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressings
Number of subjects: 76
Study 16553542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128
Study 16553542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 12716333 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan/2% copolymer dentifrice
Number of subjects: 504
Study 12716333 — intervention group
Group type: COMPARATOR
Intervention: Control group (unspecified)
Number of subjects: 504
Study 16100152 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training plus activity training
Number of subjects: 43
Study 16100152 — intervention group
Group type: COMPARATOR
Intervention: Exercise training plus lecture series
Number of subjects: 43
Study 16100152 — intervention group
Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 43